Rhumbline Advisers acquired a new stake in shares of Magenta Therapeutics Inc (NASDAQ:MGTA) during the 1st quarter, HoldingsChannel reports. The firm acquired 15,342 shares of the company’s stock, valued at approximately $253,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Harvard Management Co. Inc. raised its holdings in shares of Magenta Therapeutics by 23.7% during the fourth quarter. Harvard Management Co. Inc. now owns 411,379 shares of the company’s stock valued at $2,345,000 after purchasing an additional 78,769 shares during the period. Bessemer Group Inc. acquired a new position in shares of Magenta Therapeutics during the fourth quarter valued at about $1,352,000. Vanguard Group Inc. raised its holdings in shares of Magenta Therapeutics by 92.6% during the third quarter. Vanguard Group Inc. now owns 144,456 shares of the company’s stock valued at $1,735,000 after purchasing an additional 69,456 shares during the period. Casdin Capital LLC raised its holdings in shares of Magenta Therapeutics by 17.4% during the fourth quarter. Casdin Capital LLC now owns 2,643,317 shares of the company’s stock valued at $15,067,000 after purchasing an additional 392,499 shares during the period. Finally, BlackRock Inc. raised its holdings in shares of Magenta Therapeutics by 224.2% during the fourth quarter. BlackRock Inc. now owns 556,381 shares of the company’s stock valued at $3,170,000 after purchasing an additional 384,752 shares during the period. Hedge funds and other institutional investors own 63.62% of the company’s stock.

Shares of NASDAQ MGTA opened at $14.66 on Friday. Magenta Therapeutics Inc has a 1-year low of $5.31 and a 1-year high of $21.00.

Magenta Therapeutics (NASDAQ:MGTA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.11. As a group, sell-side analysts forecast that Magenta Therapeutics Inc will post -2.03 earnings per share for the current year.

In related news, Director Bruce Booth sold 14,245 shares of the company’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $17.86, for a total value of $254,415.70. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 10.90% of the company’s stock.

Several brokerages have recently weighed in on MGTA. Zacks Investment Research lowered shares of Magenta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, March 27th. Wedbush reiterated an “outperform” rating and set a $22.00 price objective on shares of Magenta Therapeutics in a report on Friday, May 10th. Goldman Sachs Group lowered shares of Magenta Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $17.00 to $16.00 in a report on Sunday, March 24th. They noted that the move was a valuation call. Finally, Raymond James began coverage on shares of Magenta Therapeutics in a report on Thursday, March 14th. They set an “outperform” rating on the stock. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Magenta Therapeutics presently has a consensus rating of “Buy” and an average target price of $19.00.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.watchlistnews.com/rhumbline-advisers-purchases-shares-of-15342-magenta-therapeutics-inc-nasdaqmgta/3041348.html.

Magenta Therapeutics Profile

Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.

Featured Story: How does new data get added to a blockchain?

Want to see what other hedge funds are holding MGTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Magenta Therapeutics Inc (NASDAQ:MGTA).

Institutional Ownership by Quarter for Magenta Therapeutics (NASDAQ:MGTA)

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.